Objective: The literature is inconsistent regarding the role of chronic obstructive pulmonary disease (COPD) as a risk factor for blood product transfusion during coronary artery bypass graft (CABG). One reason may be lack of objective criteria to define COPD in previously published reports. We examined the role of COPD as a risk factor for transfusion using a strict definition based on objective pulmonary function test (PFT) data. Methods: We identified 180 patients, who underwent primary isolated non-emergent CABG and had PFTs performed preoperatively. COPD was defined as forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) <70% and further stratified into mild/moderate/severe/very severe based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Patients with and without COPD were compared with respect to preoperative and postoperative characteristics and transfusion requirements. Results: The overall transfusion rate was 59.4% (107/180). COPD patients (31.1%, 56/180) were older (66.6 AE 11.4 vs 62.3 AE 10.3 years, p = 0.01), had lower body mass index (BMI) (28.5 AE 5.8 vs 31.7 AE 6.0 kg/m 2 , p = 0.001), and were more often smokers (51.8% vs 36.3%, p = 0.05). COPD patients had shorter cardiopulmonary bypass (CPB) times (99.4 AE 27.9 vs 110.9 AE 32.4 min, p = 0.02), but left internal mammary artery (LIMA) use, number of bypass grafts, mortality, and postoperative complications were similar ( p > 0.05). Transfusion rates were similar for patients with and without COPD. Further stratification into mild/moderate/severe/very severe COPD failed to identify COPD as a predictor of blood transfusion. Conclusions: Using objective PFT data, our study clarifies the disagreement in the literature with respect to the role of COPD as a risk factor for transfusion in CABG. Decreased pulmonary function does not appear to increase risk of transfusion during CABG, even for patients with severe COPD. #
Introduction
Allogenic red blood cell (RBC) transfusion has consistently been identified as a risk factor for coronary artery bypass grafts surgery (CABG)-related post-surgical adverse outcomes [1] . Transfusion is known to be an independent risk factor for early mortality [2] . In addition, multiple transfusion-related morbidities following cardiac surgery have been identified, including longer hospital stays, increased risk of infection, higher rate of pulmonary complications, prolonged ventilation, stroke, renal failure, atrial fibrillation, and myocardial infarction [3] [4] [5] .
Coronary artery bypass surgery remains one of the highest in use of blood products, with reported transfusion rates between 7% and 97% [6] . More recently, Maddux et al. [7] reported transfusion rates of 40.8% for first-time isolated CABG. Several initiatives have been developed in an effort to curtail the use of blood products. In 2007, the Society of Thoracic Surgeons (STS) announced formal guidelines for transfusion during cardiac surgery (http://www.sts.org/ sections/aboutthesociety/practiceguidelines/bloodconservation). Several institutions have developed protocols to standardize clinical decision making to decrease the number of blood transfusions [8] . Predictive models of the need for blood transfusion have been published to help target patients for blood conservation strategies [9, 10] .
Multiple risk factors for blood transfusion have been identified, including female gender, age >65 years, low body surface area, preoperative hemoglobin on 13 g/dL or less, renal failure, left-ventricular ejection fraction 0.40 or less, emergent operation, redo procedure, number of grafts, and cardiopulmonary bypass (CPB) time [2, [11] [12] [13] . The literature has remained inconsistent with respect to the role of chronic obstructive pulmonary disease (COPD) as a risk factor for blood transfusion during CABG [13, 14] . One reason for this disagreement may be lack of objective criteria to define COPD in previously published reports. COPD is a frequent comorbidity in patients presenting for CABG [4, 5] . Exploring the relationship between COPD and transfusion requirements has important clinical implications for preoperative risk stratification and application of directed blood conservation therapies. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) was launched in 1997 in collaboration with the National Heart, Lung, and Blood Institute, National Institutes of Health, USA, and the World Health Organization with the mission of improving the diagnosis, management, and prevention of COPD by formulating evidence-based guidelines. As part of these guidelines, COPD was defined and further stratified by severity using objective pulmonary function test (PFT) data. The purpose of this study was to examine the role of COPD as a risk factor for transfusion using the strict GOLD definitions, which may be found at http:// www.goldcopd.org.
Materials and methods

Patient selection
In one of the hospitals affiliated with our institution, 419 patients underwent primary, non-emergent, isolated CABG between 1 January 2008 and 31 December 2009. Forty-three percent (180/419) of the patients underwent preoperative pulmonary function testing and comprised the study population. Off-pump CABG procedures were excluded. The study was approved by our Institutional Review Board.
Definitions
In this investigation, COPD was defined and further stratified using the strict, objective definitions, according to the GOLD, as follows: mild (forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) <70% and FEV1 >80% predicted), moderate (FEV1/FVC <70% and 50% < FEV1 < 80% predicted), and severe/very severe (FEV1/FVC <70% and FEV1 <50% predicted). These definitions may be found at http://www.goldcopd.org. GOLD definitions were used with permission.
Definitions of preoperative characteristics, intra-operative variables, and postoperative outcomes were based on specifications outlined in the guidelines from the STS Version 2.61, and can be found at http://www.sts.org/sections/ stsnationaldatabase/datamanagers/congenitalheartsurgerydb/taskforce/articles/trainingmanual2.61.html.
Statistical methods
Descriptive statistics including means, medians, standard deviations, and ranges as well as frequency distributions were examined for the variables of interest. Differences between the COPD and no COPD patients were assessed using chi-squared tests of independence, independent groups' ttests, and Wilcoxon rank-sum tests, depending on the distributional characteristics of the variables being examined. Specifically, the Wilcoxon rank-sum tests were used in comparing the groups regarding measures of time. Spearman correlation coefficients were used to assess the relationship between COPD severity and blood product use. Logistic regression was used to determine whether COPD status was predictive of blood transfusions (intra-operatively, postoperatively, or at anytime). Preoperative characteristics and intra-operative/postoperative variables that approached statistical significance ( p < 0.10) were then included as covariates to adjust for these potential group differences. A secondary analysis was also performed to adjust for other previously identified predictors of transfusion. These additional predictors included age, female gender, low preoperative hematocrit, elevated creatinine, and decreased ejection fraction. Results were considered statistically significant for p < 0.05.
Results
The preoperative characteristics of patients with and without COPD are shown in Table 1 . Overall, patients had a mean age of 63.6 years, 94% (170/180) were Caucasian, 67% (121/180) were male, 41% (74/180) were current/recent smokers (within the year prior to surgery), and 41% (74/180) were diabetic. Patients with COPD were older (66.6 AE 11.4 vs 62.3 AE 10.3 years, p = 0.01), more often were smokers (51.8% vs 36.3%, p = 0.05), and had slightly lower body mass indices (BMIs) (28.5 AE 5.8 vs 31.7 AE 6.0 kg/m 2 , p = 0.001) compared with patients without COPD. There was no statistically significant difference between the two groups with respect to gender, race, diabetes mellitus, atrial fibrillation, myocardial infarction, admission status, preoperative hematocrit, and preoperative ejection fraction. No patients in either group were on warfarin within 48 h preoperatively. In addition, the two groups were similar with respect to preoperative use of aspirin (94.4% vs 92.6%, p = 0.7577), adenosine diphosphate (ADP) inhibitor within 5 days (5.4% vs 7.3%, p = 0.7565), and anti-platelet agents within 5 days (0% vs 1.6%, p = 1.0000) ( Table 2) . The distribution of patients with respect to PFT results is shown in Table 3 . Using the GOLD definitions, 31.1% (56/180) had COPD. Specifically, 7.2% (13/180) had mild COPD, 14.4% (26/180) had moderate COPD, and 9.4% (17/180) had severe/ very severe COPD. Table 4 shows the intra-operative and postoperative variables. Overall, the outcomes of this cohort of patients undergoing primary, isolated, non-emergent CABG were excellent. Thirty-day mortality was 0%, average length of stay was 7 days, and postoperative complications were infrequent, and included four re-operations for bleeding/ tamponade, six patients with prolonged ventilation, four strokes, one pneumonia, one renal failure requiring dialysis, and 43 patients with atrial fibrillation (23.9%). Patients with and without COPD did not differ with respect to postoperative complications. COPD patients had shorter CPB time (99.4 AE 27.9 vs 110.9 AE 32.4 min, p = 0.02) and aortic crossclamp time (76.4 AE 22.8 vs 84.2 AE 26.8 min, p = 0.06). The two groups were similar with respect to left internal mammary artery (LIMA) use, mean number of bypass grafts, and lowest intra-operative hematocrit. Furthermore, the two groups were similar with respect to use of postoperative anticoagulation regimens with the exception of the higher likelihood of COPD patients to receive Lovenox as a prophylaxis for deep vein thrombosis (DVT) (8.9% vs 1.6%, p = 0.0309) ( Table 2) .
Intra-operative, postoperative, and overall transfusion data with respect to presence of COPD are outlined in Figs. 1-3 , respectively. The COPD and no COPD groups did not exhibit a statistically significant difference with respect to the proportion of subjects requiring packed RBC (PRBC) transfusion intra-operatively (21.4% vs 26.6%, p = 0.4571), postoperatively (51.8% vs 47.6%, p = 0.6013), or at anytime during the hospital stay (60.7% vs 55.6%, p = 0.5245). Similar All values presented as n(%). results were found when examining transfusion of freshfrozen plasma (FFP) intra-operatively (3.6% vs 4.8%, p = 1.000), postoperatively (1.8% vs 6.5%, p = 0.2773), and at anytime (5.4% vs 9.7%, p = 0.3980), as well as platelets transfused intra-operatively (8.9% vs 7.3%, p = 0.7658), postoperatively (7.1% vs 6.5%, p = 1.000), or at anytime (14.3% vs 12.1%, p = 0.6838). In addition, among patients who received transfusion at anytime, the median number of blood product units was the same for patients with and without COPD (two units for PRBC, two units for FFP, and one unit for platelets). Furthermore, COPD severity was not statistically significantly related to having an RBC transfusion either intraoperatively (r = À0.04, p = 0.5856), postoperatively (r = 0.02, p = 0.7737), or at anytime (r = 0.03, p = 0.6573). In similar fashion, no statistically significant relationships were found between COPD severity and the use of FFP and platelets, either intra-operatively, postoperatively, or at anytime.
Having COPD was not predictive of having a transfusion at anytime (odds ratio (OR) = 1.23, 95% confidence interval (CI) 0.65-2.34) from a univariate standpoint. Following adjustment for variables that were statistically significant, or approached statistical significance, on univariate analysis (i.e., age, BMI, smoker within 1 year prior to surgery, CPB time, aortic cross-clamp time, and the prophylactic use of Lovenox postoperatively) COPD was still not statistically significantly predictive of having a transfusion at anytime (OR = 0.87, 95% CI 0.42-1.80), p = 0.7029. We also used logistic regression to see whether adjusting for other known predictors (i.e., female gender, low preoperative hematocrit, elevated creatinine, and decreased ejection fraction) might influence this relationship. The adjusted OR from this multiple logistic regression model was OR = 1.28, 95% CI 0.53-3.12, and p = 0.5802. Similarly, adjustment for these covariates and other predictors did not have an appreciable impact on the relationship between COPD and postoperative transfusion (unadjusted OR = 1.18, 95% CI 0.63-2.23; adjusted OR = 1.25, 95% CI 0.57-2.74) or intra-operative transfusion (unadjusted OR = 0.75, 95% CI 0.35-1.60; adjusted OR = 0.86, 95% CI 0.33-2.26).
Discussion
Although COPD has traditionally been associated with polycythemia, there is a growing body of literature suggesting that anemia may be more prevalent than initially thought, occurring in 13-33% of patients with COPD [15] [16] [17] [18] . Anemia in COPD has been postulated to result from the systemic inflammatory state associated with this disease, similar to other entities that cause anemia of chronic disease via decreased RBC production and life span [18, 19] . Low hematocrit has been identified as a strong predictor of poor prognosis [17] , and as a risk factor for mortality after elective abdominal aortic aneurysm resection in patients with COPD [20] . RBC transfusion in anemic patients with COPD has been shown to decrease the minute ventilation and the work of breathing in ventilated patients [21] . Following cardiac surgery, the presence of anemia in patients with COPD may worsen dyspnea and lead to reduced exercise tolerance. Therefore, patients with COPD may be particularly unable to tolerate the decrease in oxygen-carrying capacity associated with CPB-related hemodilution and RBC mechanical destruction from the bypass circuit. COPD has been identified as a predictor of transfusion in various surgical procedures [22, 23] . Whether patients with COPD are more likely to receive blood transfusion after cardiac surgery remains a matter of controversy. Two factors responsible for this debate are: (1) lack of clear distinction in the literature with respect to the influence of smoking versus COPD on transfusion risk and (2) lack of objective criteria to define COPD in previously published reports. Surgenor et al. identified smoking, but not COPD, as a risk factor for blood transfusion, whereas a number of other studies found that smokers were less likely to get transfused compared with non-smokers [3, 14, 24, 25] . Similarly, COPD has been identified as a risk factor for transfusion in CABG by some investigators [1, 4] , whereas others have found a similar transfusion risk between patients with and without COPD [10, 13] . For example, Scott et al. [4] reported a statistically significant difference ( p < 0.001) in likelihood of transfusion with respect to COPD, where approximately 72% of patients with COPD received transfusion, compared with approximately 60% of those without COPD. This study, in addition to that by Elmistekawy et al. [13] , who found no predictive relationship of COPD in transfusion, failed to objectively define COPD. Though Karkouti et al. [10] defined COPD as patients having an FEV1 <75%, only 43/56 patients with COPD had transfusion charted, and of these 43, only 11 patients with COPD received transfusion. The lack of large numbers of patients in these studies, in addition to the lack of reported PFT values, complicates the ability to draw conclusions regarding a potential relationship between the presence of COPD and transfusion requirements in CABG.
The goal of our study was to determine if COPD is an independent risk factor for transfusion during CABG, using the GOLD definitions and objective data for COPD. To the best of our knowledge, this is the first study that investigates the role of COPD as an independent risk factor for blood product use in primary, isolated, non-emergent CABG, using strict definitions of COPD, based on objective PFT data. We found that the proportion of COPD and non-COPD patients transfused, both intra-operatively and postoperatively, were similar. Further stratifying patients by severity of COPD also did not show COPD to be predictive of transfusion. There was no difference with respect to PRBCs, FFP, or platelets within all categories of severity of COPD. The lack of a positive association between the presence of COPD and transfusion remained, even after controlling for covariates and known predictors.
The role of smoking as a risk factor for transfusion is difficult to study. The definitions of past versus present tobacco use are not uniform across published reports [14, 24, 25] . The heterogeneity between studies makes meaningful comparisons challenging. Therefore, it remains unclear if active tobacco use itself is a contributing factor. We defined smoking history according to the current version of the STS database as tobacco product use within the last 1 year (http://www.sts.org/sections/stsnationaldatabase/ datamanagers/congenitalheartsurgerydb/taskforce/articles/ trainingmanual2.61.html). Patients with extensive smoking history prior to the last year from the time of their surgery were considered non-smokers. This definition limited our ability to explore the relationship between smoking itself and transfusion risk.
While the use of anticoagulants could potentially influence the need for transfusion, little difference was noted between the COPD and non-COPD patients in our study. The only difference noted with respect to this variable between the groups was in the postoperative use of Lovenox for DVT prophylaxis. While we do not feel that this should contribute to bleeding risk, we did include it in the multiple logistic regression model as a covariate.
Our study has several limitations. It is a retrospective report from a single institution and therefore does not account for any inter-institutional variability in physician transfusion practices. In addition, at our institution we do not have an implemented transfusion algorithm. Therefore, the decision to administer blood products is individualized and some intra-institutional variability in physician transfusion practices may exist.
Our small sample size of patients with preoperative PFT data represented less than half of the cohort of patients undergoing primary non-emergent CABG. This raises the possibility of selection bias. We therefore compared the baseline characteristics of patients who had PFTs performed, and those who did not have PFTs performed. These groups did not statistically significantly differ with respect to age, race, BMI, preoperative dialysis, preoperative hematocrit, or preoperative creatinine. A greater proportion of those with PFTs performed were female (32.8% vs 23.0%, p = 0.0262), were smokers (41.1% vs 20.9%, p = 0.0001), had atrial fibrillation (6.7% vs 2.1%, p = 0.0188), had a myocardial infarction (52.8% vs 34.3%, p = 0.0002), and underwent urgent surgery (52.8% vs 39.9%, p = 0.00062). In addition, although statistically significant, the small difference in ejection fraction between patients with and without preoperative PFT data has little clinical relevance (50.3% vs 53.7%, p = 0.0078). However, there was no statistically significant difference between those with and without preoperative PFT data in the likelihood of transfusion (at anytime) for PRBCs (57.2% vs 54.4%; p = 0.5640), FFP plasma (8.3% vs 10.5%, p = 0.4633), or platelets (12.8% vs 12.1%, p = 0.8431).
In this investigation, we report a lack of a statistically significant association of diminished pulmonary function and transfusion risk in CABG. This finding must be viewed in the context of our sample size. Nearly two-thirds (67%) of patients with COPD were transfused any blood products at anytime compared with 58% of those without COPD. Although the magnitude of this difference is small and not statistically significant, it may bear some clinical relevance. Despite these limitations, our study provides important information by addressing the relationship between transfusion risk in CABG and the presence of COPD defined objectively based on PFT data.
